• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

AAO 2023: Centricity Vision CEO shares company updates

News
Video

Rob Thornhill, CEO of Centricity Vision spoke with the Ophthalmology Times team about the company's newest developments at this year's American Academy of Ophthalmology meeting.

Rob Thornhill, CEO of Centricity Vision spoke with the Ophthalmology Times team about the company's newest developments at this year's American Academy of Ophthalmology meeting.

Video Transcript

Editor's note - This transcript has been edited for clarity.

Rob Thornhill:

Good morning. My name is Rob Thornhill. I'm the CEO of Centricity Vision, the developer and manufacturer of ZEPTO and ZEPTOLink IOL positioning systems. Were excited to announce the commercial launch of our newest innovation ZEPTOLink here at the Academy of Ophthalmology in San Francisco. ZEPTOLink, as well as our legacy ZEPTO systems, are the first and only devices that create an instantaneous capsulotomy with precise 360 degree overlap and superior capsular edge strength, making our technology ideal for advanced technology intraocular lenses and complex cases, requiring enhanced precision. ZEPTOLink combines the clinically proven ZEPTO technology with any phacoemulsification device. This combination saves time and space in the operating room. A combination of 12 new and existing accounts, as well as 22 surgeons participated in our soft launch over the last 3 months and successfully completed over 500 ZEPTOLink cases. The surgeons liked the intuitive use of the phaco foot pedal that allowed them to precisely control suction, energy delivery, and irrigation. Universally, they recognize the enhanced speed of the ZEPTO system which leads to enhanced workflow efficiency, especially when compared to a laser system. With the increasing cost of all goods and services, including cataract surgery, ZEPTO technology at 1/10 the capital cost in one half the per use cost of a laser provide surgeons and their patients with a cost effective alternative when considering advanced technology IOL surgery. Thank you.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.